Treatment response of differentiated thyroid carcinoma with negative preablative stimulated thyroglobulin and iodine-positive lymph node after the first radioablation and influence factors analysis
10.3760/cma.j.issn.2095-2848.2020.01.005
- VernacularTitle: 首次131I治疗后淋巴结显影伴治疗前刺激性Tg阴性的分化型甲状腺癌的治疗反应及影响因素分析
- Author:
Chenghui LU
1
;
Jiao LI
;
Xinfeng LIU
;
Guoqiang WANG
;
Zenghua WANG
;
Xufu WANG
Author Information
1. Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University, Qingdao 266003, China
- Publication Type:Clinical Trail
- Keywords:
Thyroid neoplasms;
Radiotherapy;
Iodine radioisotopes;
Thyroglobulin
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2020;40(1):21-26
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the response to 131I therapy and to explore the influence factors in postoperative differentiated thyroid carcinoma (DTC) patients with negative preablative stimulated thyroglobulin (psTg) and iodine-positive lymph node after the first radioablation.
Methods:From May 2016 to October 2018, 108 DTC patients (28 males, 80 females, age: (45.7±10.4) years) with negative psTg who underwent 131I treatment for the first time in the Affiliated Hospital of Qingdao University were retrospectively enrolled. All patients had iodine-positive lymph nodes, which were showed by SPECT/CT imaging 5-6 d after 131I treatment. The treatment response was evaluated at 6-24 month after 131I treatment. Patients were divided into excellent response (ER) group and non-excellent response (non-ER) group according to the response to the first 131I treatment. Independent-sample t test, χ2 test and Mann-Whitney U test were used to analyze differences of factors (e.g. age, gender, extraglandular infiltration) between the 2 groups, and then multivariate logistic regression was performed to find the influence factors for treatment response. The receiver operating characteristic (ROC) curve was employed to evaluate the predictive value of the iodine-positive lymph node size in 131I treatment response.
Results:A total of 82 patients (75.93%, 82/108) achieved ER, and 26 (24.07%, 26/108) was non-ER patients. There were significant differences in age (t=-2.540, P=0.016), extraglandular infiltration (χ2=5.764, P=0.016), T stage (χ2=19.857, P<0.001), N stage (χ2=14.145, P=0.001), risk stratification of recurrence (χ2=11.487, P=0.003), ultrasound results before 131I treatment (χ2=44.819, P<0.001), dose of the first 131I treatment (U=780.0, P=0.018), size (long diameter) of iodine-positive lymph node (U=184.0, P<0.001), and psTg level (U=776.0, P=0.037) between ER and non-ER groups. Multivariate logistic regression showed that age, size of iodine-positive lymph node and ultrasound results before 131I treatment were closely related to 131I treatment response. The odds ratio (OR) values (95% CI) were 1.123 (1.025-1.231), 4.275 (1.893-9.653) and 260.86 (8.123-8 376.764), respectively. The sensitivity, specificity, accuracy, positive predictive value and negative predictive value for non-ER were 100%(26/26), 70.73%(58/82), 77.78%(84/108), 52.00%(26/50) and 100%(58/58) respectively when the cut-off value of iodine-positive lymph node size was 5.5 mm.
Conclusion:The response of some DTC patients with negative psTg and iodine-positive lymph node after the first radioablation were non-ER. Age, ultrasound results before 131I treatment and size of iodine-positive lymph node are sensitive indicators for predicting clinical outcome in DTC patients with negative psTg and iodine-positive lymph node after the first radioablation.
